Balance Sheet Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 29/08/2026 +04			5-day change	1st Jan Change
13.38 ^USD	-6.56%		-6.43%	-14.67%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

bfd9604fae8a13447.kK5bsEXP_H5X6Ow5blUmNuvilu-bFuvbgiAJEO9eqm4.8vwq5XSujykAkaEPPBEWZ4ew-KnifoK6smM6RYYx5F_U7DX6NJzNLhnfoQ

Published financial data: MONTE ROSA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Revenues	-	-	-	75.62M	124M
Total Revenues	-	-	-	75.62M	124M
Cost of Goods Sold, Total	-	-	-	113M	134M
Gross Profit	-	-	-	-37.24M	-10.03M
Selling General & Admin Expenses, Total	15.73M	35.12M	39.94M	43.87M	44.18M
R&D Expenses	57.16M	77.26M	103M	-	-
Other Operating Expenses, Total	72.88M	112M	143M	43.87M	44.18M
Operating Income	-72.88M	-112M	-143M	-81.11M	-54.21M
Interest Expense, Total	-	-	-	-	-
Interest And Investment Income	46K	3.76M	9.33M	10.57M	12.94M
Net Interest Expenses	46K	3.76M	9.33M	10.57M	12.94M
Currency Exchange Gains (Loss)	-162K	10K	-930K	416K	1.48M
Other Non Operating Income (Expenses)	-960K	-	-	-	-
EBT, Excl. Unusual Items	-73.96M	-109M	-135M	-70.13M	-39.78M
Gain (Loss) On Sale Of Investments	-	-	-131K	-	-
Gain (Loss) On Sale Of Assets	-	109K	24K	-	59K
EBT, Incl. Unusual Items	-73.96M	-109M	-135M	-70.13M	-39.72M
Income Tax Expense	-	-	338K	2.57M	-1.1M
Earnings From Continuing Operations	-73.96M	-109M	-135M	-72.7M	-38.63M
Net Income to Company	-73.96M	-109M	-135M	-72.7M	-38.63M
Net Income - (IS)	-73.96M	-109M	-135M	-72.7M	-38.63M
Net Income to Common Incl Extra Items	-73.96M	-109M	-135M	-72.7M	-38.63M
Net Income to Common Excl. Extra Items	-73.96M	-109M	-135M	-72.7M	-38.63M
Per Share Items
Net EPS - Basic	-2.96	-2.3	-2.63	-0.98	-0.46
Basic EPS - Continuing Operations	-2.96	-2.3	-2.63	-0.98	-0.46
Basic Weighted Average Shares Outstanding	25M	47.23M	51.4M	73.91M	83.07M
Net EPS - Diluted	-2.96	-2.3	-2.63	-0.98	-0.46
Diluted EPS - Continuing Operations	-2.96	-2.3	-2.63	-0.98	-0.46
Diluted Weighted Average Shares Outstanding	25M	47.23M	51.4M	73.91M	83.07M
Normalized Basic EPS	-1.85	-1.44	-1.64	-0.59	-0.3
Normalized Diluted EPS	-1.85	-1.44	-1.64	-0.59	-0.3
Supplemental Items
EBITDA	-70.75M	-109M	-137M	-72.99M	-45.85M
EBITA	-72.88M	-112M	-143M	-81.11M	-54.21M
EBIT	-72.88M	-112M	-143M	-81.11M	-54.21M
EBITDAR	-68.45M	-99.82M	-128M	-62.54M	-36.63M
Effective Tax Rate - (Ratio)	-	-	-0.25	-3.66	2.76
Current Domestic Taxes	-	-	-	-	-1.1M
Total Current Taxes	-	-	-	-	-1.1M
Normalized Net Income	-46.22M	-67.88M	-84.32M	-43.83M	-24.86M
Non-Cash Pension Expense	0	19K	198K	174K	140K
Supplemental Operating Expense Items
General and Administrative Expenses	15.73M	26.3M	30.48M	33.42M	34.96M
Research And Development Expense From Footnotes	57.16M	85.06M	111M	122M	142M
Net Rental Expense, Total	2.3M	8.82M	9.46M	10.46M	9.22M
Stock-Based Comp., COGS (Total)	-	-	-	10.63M	10.86M
Stock-Based Comp., R&D Exp. (Total)	2.61M	5.58M	8.94M	-	-
Stock-Based Comp., G&A Exp. (Total)	2.59M	6.08M	7.73M	7.5M	8M
Total Stock-Based Compensation	5.2M	11.66M	16.67M	18.13M	18.86M

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	346M	54.91M	128M	224M	130M
Short Term Investments	-	208M	104M	148M	247M
Total Cash And Short Term Investments	346M	263M	232M	372M	377M
Other Receivables	-	7.66M	505K	173K	11.6M
Total Receivables	-	7.66M	505K	173K	11.6M
Prepaid Expenses	2.6M	4.44M	3.29M	5.12M	4.48M
Restricted Cash	-	960K	-	-	-
Total Current Assets	349M	276M	236M	377M	393M
Gross Property Plant And Equipment	15.03M	68.16M	74.86M	76.68M	77.98M
Accumulated Depreciation	-2.7M	-6.25M	-12.24M	-20.36M	-27.61M
Net Property Plant And Equipment	12.32M	61.91M	62.61M	56.31M	50.37M
Other Long-Term Assets, Total	5.34M	4.6M	4.93M	4.98M	5.1M
Total Assets	366M	342M	304M	439M	449M
Liabilities
Accounts Payable, Total	6.56M	7.86M	11.15M	17.22M	3.55M
Accrued Expenses, Total	9.24M	9.56M	12.93M	15.43M	25.12M
Short-term Borrowings	-	-	-	-	-
Current Portion of Leases	-	3.13M	3.16M	3.71M	4.4M
Unearned Revenue Current, Total	-	-	17.68M	117M	29.57M
Other Current Liabilities	840K	5.02M	1.67M	3.35M	1.58M
Total Current Liabilities	16.64M	25.57M	46.59M	157M	64.21M
Long-Term Leases	-	43.87M	42.88M	39M	34.79M
Unearned Revenue Non Current	-	-	32.32M	16.15M	111M
Pension & Other Post Retirement Benefits	2.18M	1.53M	2.71M	3.7M	5.26M
Total Liabilities	18.81M	70.98M	125M	216M	216M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	5K	5K	5K	6K	7K
Additional Paid In Capital	472M	504M	548M	665M	714M
Retained Earnings	-122M	-231M	-366M	-439M	-477M
Comprehensive Income and Other	-2.02M	-1.75M	-2.72M	-3.36M	-3.83M
Total Common Equity	348M	271M	179M	223M	233M
Total Equity	348M	271M	179M	223M	233M
Total Liabilities And Equity	366M	342M	304M	439M	449M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	46.37M	49.24M	50.14M	61.51M	80.02M
ECS Total Common Shares Outstanding	46.54M	49.32M	50.14M	61.51M	65.54M
Book Value / Share	7.47	5.5	3.57	3.62	3.56
Tangible Book Value	348M	271M	179M	223M	233M
Tangible Book Value Per Share	7.47	5.5	3.57	3.62	3.56
Total Debt	0	47M	46.04M	42.72M	39.19M
Net Debt	-346M	-216M	-186M	-329M	-338M
Debt Equivalent of Unfunded Proj. Benefit Obligation	2.18M	1.53M	2.71M	3.7M	5.26M
Debt Equivalent Oper. Leases	18.4M	70.58M	75.66M	83.64M	73.76M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	13.06M	18.65M	24.23M	27.4M	29.81M
Full Time Employees	93	123	133	134	150

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-73.96M	-109M	-135M	-72.7M	-38.63M
Depreciation & Amortization - CF	2.13M	3.74M	6.22M	10.22M	10.86M
Depreciation & Amortization, Total	2.13M	3.74M	6.22M	10.22M	10.86M
(Gain) Loss From Sale Of Asset	17K	-109K	-24K	-	-59K
(Gain) Loss on Sale of Investments - (CF)	-	-1.94M	-3.78M	-2.95M	-2.14M
Stock-Based Compensation (CF)	5.2M	11.66M	16.67M	18.13M	18.86M
Other Operating Activities, Total	960K	4.81M	-	-2.1M	-2.5M
Change In Accounts Receivable	-	-187K	1.9M	332K	-4.43M
Change In Accounts Payable	-706K	-744K	5.76M	6.25M	-13.71M
Change in Unearned Revenues	-	-	50M	83.38M	7.52M
Change in Other Net Operating Assets	6.99M	-1.2M	14.81M	1.44M	1.42M
Cash from Operations	-59.36M	-92.47M	-43.8M	42M	-22.8M
Capital Expenditure	-9.73M	-12.91M	-19.04M	-3.99M	-4.7M
Sale of Property, Plant, and Equipment	79K	109K	62K	-	-
Investment in Marketable and Equity Securities, Total	-	-206M	108M	-40.46M	-97.13M
Cash from Investing	-9.65M	-219M	88.8M	-44.45M	-102M
Short Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Issuance of Common Stock	256M	20.83M	2.61M	52.53M	30.71M
Issuance of Preferred Stock	143M	-	-	-	-
Other Financing Activities, Total	-21.23M	-364K	24.88M	46.36M	-357K
Cash from Financing	378M	20.47M	27.49M	98.89M	30.35M
Net Change in Cash	309M	-291M	72.49M	96.44M	-94.28M
Supplemental Items
Levered Free Cash Flow	-61.29M	-72.4M	-55.47M	81.97M	-113M
Unlevered Free Cash Flow	-61.29M	-72.4M	-55.47M	81.97M	-113M
Change In Net Working Capital	13.34M	4.66M	-30.25M	-108M	104M
Net Debt Issued / Repaid	-	-	-	-	-

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-21.92	-19.82	-27.72	-13.66	-7.64
Return on Total Capital	-24.85	-21.1	-32.95	-20.65	-12.6
Return On Equity %	-40.35	-35.06	-60.07	-36.15	-16.94
Return on Common Equity	-49.51	-35.06	-60.07	-36.15	-16.94
Margin Analysis
Gross Profit Margin %	-	-	-	-49.25	-8.11
SG&A Margin	-	-	-	58.01	35.72
EBITDA Margin %	-	-	-	-96.52	-37.08
EBITA Margin %	-	-	-	-107.26	-43.83
EBIT Margin %	-	-	-	-107.26	-43.83
Income From Continuing Operations Margin %	-	-	-	-96.14	-31.23
Net Income Margin %	-	-	-	-96.14	-31.23
Net Avail. For Common Margin %	-	-	-	-96.14	-31.23
Normalized Net Income Margin	-	-	-	-57.96	-20.1
Levered Free Cash Flow Margin	-	-	-	108.4	-91.42
Unlevered Free Cash Flow Margin	-	-	-	108.4	-91.42
Asset Turnover
Asset Turnover	-	-	-	0.2	0.28
Fixed Assets Turnover	-	-	-	1.27	2.32
Short Term Liquidity
Current Ratio	20.96	10.79	5.07	2.4	6.12
Quick Ratio	20.8	10.58	5	2.37	6.05
Operating Cash Flow to Current Liabilities	-3.57	-3.62	-0.94	0.27	-0.36
Average Days Payable Outstanding	-	-	-	46	28.34
Long Term Solvency
Total Debt/Equity	-	17.32	25.68	19.16	16.82
Total Debt / Total Capital	-	14.76	20.44	16.08	14.4
LT Debt/Equity	-	16.16	23.92	17.49	14.93
Long-Term Debt / Total Capital	-	13.78	19.03	14.68	12.78
Total Liabilities / Total Assets	5.14	20.73	40.99	49.19	48.05
EBIT / Interest Expense	-	-	-	-	-
EBITDA / Interest Expense	-	-	-	-	-
(EBITDA - Capex) / Interest Expense	-	-	-	-	-
Total Debt / EBITDA	-	-0.47	-0.36	-0.68	-1.07
Net Debt / EBITDA	4.89	2.16	1.46	5.27	9.22
Total Debt / (EBITDA - Capex)	-	-0.42	-0.31	-0.64	-0.95
Net Debt / (EBITDA - Capex)	4.3	1.91	1.27	4.95	8.18
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-	-	63.54
Gross Profit, 1 Yr. Growth %	-	-	-	-63.97	-73.07
EBITDA, 1 Yr. Growth %	157.53	53.55	26.19	-46.76	-37.18
EBITA, 1 Yr. Growth %	160.2	54.2	27.52	-43.4	-33.17
EBIT, 1 Yr. Growth %	160.2	54.2	27.52	-43.4	-33.17
Earnings From Cont. Operations, 1 Yr. Growth %	106.13	46.71	24.75	-46.29	-46.87
Net Income, 1 Yr. Growth %	106.13	46.71	24.75	-46.29	-46.87
Normalized Net Income, 1 Yr. Growth %	106.13	46.85	24.21	-48.02	-43.27
Diluted EPS Before Extra, 1 Yr. Growth %	-87.49	-22.34	14.63	-62.65	-52.73
Net Property, Plant and Equip., 1 Yr. Growth %	166.6	402.29	1.14	-10.06	-10.55
Total Assets, 1 Yr. Growth %	641.89	-6.54	-11.28	44.44	2.26
Tangible Book Value, 1 Yr. Growth %	-813.17	-21.9	-33.96	24.37	4.54
Common Equity, 1 Yr. Growth %	-813.17	-21.9	-33.96	24.37	4.54
Cash From Operations, 1 Yr. Growth %	157.51	55.76	-52.63	-195.88	-154.29
Capital Expenditures, 1 Yr. Growth %	187.16	32.67	47.48	-79.06	17.85
Levered Free Cash Flow, 1 Yr. Growth %	-906.38	18.13	-23.39	-253.59	-237.93
Unlevered Free Cash Flow, 1 Yr. Growth %	-906.38	18.13	-23.39	-253.59	-237.93
Compound Annual Growth Rate Over Two Years
Gross Profit, 2 Yr. CAGR %	-	-	-	-	-68.85
EBITDA, 2 Yr. CAGR %	-13.73	98.86	39.2	-18.03	-42.17
EBITA, 2 Yr. CAGR %	-12.84	100.31	40.23	-15.04	-38.5
EBIT, 2 Yr. CAGR %	-12.84	100.31	40.23	-15.04	-38.5
Earnings From Cont. Operations, 2 Yr. CAGR %	-10.77	73.9	35.28	-18.14	-46.58
Net Income, 2 Yr. CAGR %	-10.77	73.9	35.28	-18.14	-46.58
Normalized Net Income, 2 Yr. CAGR %	-10.77	73.99	35.06	-19.64	-45.7
Diluted EPS Before Extra, 2 Yr. CAGR %	-78.76	-68.83	-5.65	-34.57	-57.98
Net Property, Plant and Equip., 2 Yr. CAGR %	203.85	265.94	125.39	-4.62	-10.3
Total Assets, 2 Yr. CAGR %	474.63	163.33	-8.94	13.2	21.53
Tangible Book Value, 2 Yr. CAGR %	434.85	136.01	-28.18	-9.37	14.03
Common Equity, 2 Yr. CAGR %	434.85	136.01	-28.18	-9.37	14.03
Cash From Operations, 2 Yr. CAGR %	-10.48	100.28	-14.1	-32.61	-27.86
Capital Expenditures, 2 Yr. CAGR %	-23.48	95.18	39.88	-44.42	-50.32
Levered Free Cash Flow, 2 Yr. CAGR %	-	208.64	-4.87	6.4	45.55
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	208.64	-4.87	6.4	45.55
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	4.55	70.88	1.04	-24.99
EBITA, 3 Yr. CAGR %	-	5.42	72.31	3.63	-21.58
EBIT, 3 Yr. CAGR %	-	5.42	72.31	3.63	-21.58
Earnings From Cont. Operations, 3 Yr. CAGR %	-	5.32	55.67	-0.57	-29.13
Net Income, 3 Yr. CAGR %	-	5.32	55.67	-0.57	-29.13
Normalized Net Income, 3 Yr. CAGR %	-	5.35	55.5	-1.76	-28.45
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-67.28	-51.89	-30.72	-41.29
Net Property, Plant and Equip., 3 Yr. CAGR %	-	259.27	138.36	65.94	-6.64
Total Assets, 3 Yr. CAGR %	-	213.67	83.23	6.2	9.43
Tangible Book Value, 3 Yr. CAGR %	-	181.65	54.37	-13.75	-4.95
Common Equity, 3 Yr. CAGR %	-	181.65	54.37	-13.75	-4.95
Cash From Operations, 3 Yr. CAGR %	-	7.67	23.86	-10.9	-37.29
Capital Expenditures, 3 Yr. CAGR %	-	-8.07	77.78	-25.72	-28.6
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	93.97	10.18	16.02
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	93.97	10.18	16.02
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	-5.15	10.79
EBITA, 5 Yr. CAGR %	-	-	-	-3.3	14.12
EBIT, 5 Yr. CAGR %	-	-	-	-3.3	14.12
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-4.78	1.49
Net Income, 5 Yr. CAGR %	-	-	-	-4.78	1.49
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-5.46	2.09
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-56.83	-54.43
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	111.36	61.23
Total Assets, 5 Yr. CAGR %	-	-	-	108.65	55.48
Tangible Book Value, 5 Yr. CAGR %	-	-	-	78.95	36.75
Common Equity, 5 Yr. CAGR %	-	-	-	78.95	36.75
Cash From Operations, 5 Yr. CAGR %	-	-	-	-10.73	-0.22
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-24.83	6.76
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	71.59
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	71.59